Bicycle Therapeutics corrects COO sales to 356 shares

The amendment corrects earlier overstatements in reported sale quantities, weighted-average price and post-transaction beneficial ownership.

This filing corrects an earlier one, and you can read the original Form 4 if you want to see what changed.

Rhea-AI Filing Summary

Bicycle Therapeutics plc (BCYC) Chief Operating Officer Jennifer Scott Perry reported direct sales of 30 ordinary shares on October 5, 2026, at a weighted average price of $3.57 per share; prices ranged from $3.56 to $3.57. The sale was required to cover statutory tax withholding tied to RSU vesting and settlement. She also reported selling 326 ordinary shares at $3.78 per share on October 5, 2026, under a Rule 10b5-1 trading plan.

Insider Trade Summary 10b5-1

Net Seller: 356 shares

Net Sell 2 txns

Insider Perry Jennifer Scott

Role Chief Operating Officer

Sold 356 shs ($1K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares F1, F2, F3	30	$3.57	$107.10
Sale	Ordinary Shares F4, F2	326	$3.78	$1K

Holdings After Transaction: Ordinary Shares — 89,602 shares (Direct)

Footnotes (4)

1. F1. Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
2. F2. The original Form 4 inadvertently overstated the number of shares sold, weighted average price and the number of shares beneficially owned following the reported transactions. This amendment correctly states the number of shares sold, weighted average price and the number of shares beneficially owned following the reported transactions.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.56 to $3.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. F4. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on March 27, 2025.

Key Figures

Shares sold in sell-to-cover transaction: 30 shares Weighted average sale price: $3.57 per share Reported price range: $3.56 to $3.57 per share +3 more

6 metrics

Shares sold in sell-to-cover transaction 30 shares October 5, 2026

Weighted average sale price $3.57 per share 30-share sale on October 5, 2026

Reported price range $3.56 to $3.57 per share Prices for the 30-share sale

Shares sold under Rule 10b5-1 plan 326 shares October 5, 2026

Sale price $3.78 per share 326-share sale on October 5, 2026

Total shares sold 356 shares Two reported sales on October 5, 2026

Key Terms

RSUs, Rule 10b5-1 trading plan, weighted average price

3 terms

RSUs financial

"vesting and settlement of the RSUs"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many BCYC shares did Jennifer Scott Perry sell, and at what prices?

Jennifer Scott Perry reported two direct sales totaling 356 ordinary shares on October 5, 2026: 30 at a weighted average price of $3.57 per share, with prices ranging from $3.56 to $3.57, and 326 at $3.78 per share.

When was the plan for Jennifer Scott Perry’s 326-share BCYC sale adopted?

The Rule 10b5-1 trading plan associated with the 326-share sale was adopted on March 27, 2025.

Why was the BCYC Form 4 amended?

The amendment states that the original Form 4 inadvertently overstated the number of shares sold, the weighted average price and the number of shares beneficially owned following the reported transactions; the amendment corrects those figures.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/07/2026 - 06:25 PM Accepted by SEC EDGAR 10/07/2026 - 06:24 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Perry Jennifer Scott

(Last) (First) (Middle)

C/O BICYCLE THERAPEUTICS PLC

BLOCKS A & B, PORTWAY BUILDING

(Street)

CAMBRIDGE CB21 6GS

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
BICYCLE THERAPEUTICS PLC [ BCYC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
10/06/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	10/05/2026		S(1)		30(2)	D	$3.57(2)(3)	89,928(2)	D
Ordinary Shares	10/05/2026		S(4)		326	D	$3.78	89,602(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

2. The original Form 4 inadvertently overstated the number of shares sold, weighted average price and the number of shares beneficially owned following the reported transactions. This amendment correctly states the number of shares sold, weighted average price and the number of shares beneficially owned following the reported transactions.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.56 to $3.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on March 27, 2025.

	/s/ Travis Thompson, Attorney-in-Fact	10/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)